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Abstract
Background: The treatment results of external beam radiotherapy for intermediate and high risk prostate cancer
patients are insufficient with five-year biochemical relapse rates of approximately 35%. Several randomized trials
have shown that dose escalation to the entire prostate improves biochemical disease free survival. However,
further dose escalation to the whole gland is limited due to an unacceptable high risk of acute and late toxicity.
Moreover, local recurrences often originate at the location of the macroscopic tumor, so boosting the radiation
dose at the macroscopic tumor within the prostate might increase local control. A reduction of distant metastases
and improved survival can be expected by reducing local failure. The aim of this study is to investigate the benefit
of an ablative microboost to the macroscopic tumor within the prostate in patients treated with external beam
radiotherapy for prostate cancer.
Methods/Design: The FLAME-trial (Focal Lesion Ablative Microboost in prostatE cancer) is a single blind
randomized controlled phase III trial. We aim to include 566 patients (283 per treatment arm) with intermediate or
high risk adenocarcinoma of the prostate who are scheduled for external beam radiotherapy using fiducial markers
for position verification. With this number of patients, the expected increase in five-year freedom from biochemical
failure rate of 10% can be detected with a power of 80%. Patients allocated to the standard arm receive a dose of
77 Gy in 35 fractions to the entire prostate and patients in the experimental arm receive 77 Gy to the entire
prostate and an additional integrated microboost to the macroscopic tumor of 95 Gy in 35 fractions. The
secondary outcome measures include treatment-related toxicity, quality of life and disease-specific survival.
Furthermore, by localizing the recurrent tumors within the prostate during follow-up and correlating this with the
delivered dose, we can obtain accurate dose-effect information for both the macroscopic tumor and subclinical
disease in prostate cancer. The rationale, study design and the first 50 patients included are described.
Trial registration: This study is registered at ClinicalTrials.gov: NCT01168479
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Localised prostate cancer can be treated by radical pros-
tatectomy, brachytherapy or external beam radiotherapy.
For low risk tumors the results of external beam radio-
therapy are comparable to radical prostatectomy and
brachytherapy with freedom from biochemical failure
rates approximating 95% after 5- to 10-year follow-up
[1]. For high risk patients, external beam radiotherapy is
preferred. The outcome for intermediate and high risk
patients is insufficient with freedom from biochemical
failure ranging between 60% and 75% after 5- to 10-
years follow-up [2-4].
Several randomized trials have proven that dose esca-
lation in external beam radiotherapy improves the bio-
chemical disease free survival [2,4-6]. Pollack et al.[ 2 ]
compared the efficacy of 70 Gy versus 78 Gy on 305
patients with stage T1-3 prostate cancer. For patients
with a pretreatment PSA > 10 ng/mL the freedom from
biochemical failure rate at five year was 43% versus 62%
respectively, in favor of the higher dose group. The ran-
domized trial from Peeters et al. [4] compared 68 Gy
versus 78 Gy on 669 patients with stage T1-4 prostate
cancer. Five-year freedom from failure rate was signifi-
cantly improved from 54% to 64%. Further increase in
dose is considered to improve the treatment results
even further [2,4,7]. Dose response models suggest that
tumor areas with severe hypoxia will need very high
(ablative) doses [8]. Moreover, local recurrences often
occur at the site of the primary macroscopic tumor
[9,10], so boosting the radiation dose to the macroscopic
tumor might increase the local control. An improve-
ment in distant metastases and survival can be expected
by reducing local failure, due to the fact that local fail-
ure is associated with distant metastases and mortality
[11-13].
Dose escalation to the entire prostate is not consid-
ered feasible by reason of unacceptable toxicity risks.
This problem can be overcome by partial boosting stra-
tegies. In this way, the macroscopic tumor can be irra-
diated to a very high dose, while the dose constraints to
the rectum and bladder can be maintained [14,15]. This
approach is being used to deliver a microboost to the
dominant tumor region in a number of pilot studies
[16-19]. The dose to the macroscopic tumor is increas-
ingly escalated. The highest dose was delivered in a fea-
sibility study by Singh et al. [20] who treated 3 patients
with an ablative dose of 95 Gy to the macroscopic
tumor within the prostate with no severe toxicity (≥
grade 3).
To investigate the benefit of an ablative microboost to
the macroscopic tumor within the prostate, we started a
randomized controlled trial (the FLAME-trial: Focal
Lesion Ablative Microboost in prostatE cancer, clinical
trials: study protocol number NCT01168479). The pur-
pose of this trial is to assess whether a dose escalation
to the macroscopic tumor increases the five-year free-
dom from biochemical failure rate. Furthermore, we will
assess the influence of this dose escalation on treat-




The FLAME-trial is a multicenter randomized con-
trolled trial. Patients are recruited during the intake
consultation at the Department of Radiation Oncology
in one of the participating centers. After giving informed
consent, patients are randomized either to the standard
arm or to the experimental arm. Patients in the standard
arm receive radiotherapy according to the current stan-
dard [4], namely 77 Gy in 35 fractions of 2.2 Gy to the
whole prostate. Patients in the experimental arm receive
an additional integrated microboost to the macroscopic
tumor to a total dose of 95 Gy in 2.7 Gy fractions.
To ensure unbiased assessment of QoL measurements,
the patients are blinded to the actual treatment given
(receiving an ablative microboost or not). The treating
physician needs to be informed about the actual treat-
ment, to be able to judge the treatment plans. This is
unlikely to influence the assessment of the objective pri-
mary endpoint of the trial.
Patients
Men with histological proven intermediate or high risk
adenocarcinoma of the prostate, who will receive exter-
nal beam radiotherapy using optimal position verifica-
tion with implanted fiducial gold markers, are eligible
for the study. Intermediate or high risk is defined
according to the currently internationally accepted cri-
teria from Ash et al. [21]. Intermediate risk is defined as
patients having one factor of stage T2b-c, or Gleason
score = 7, or initial prostate-specific antigen (iPSA) =
10-20 ng/mL. Patients having more than one of these
factors or having stage T3, or Gleason score >7, or iPSA
> 20 ng/mL are defined as high risk. Patients with low
risk tumors are not included in this study, because the
treatment outcome for this group is already excellent
with a 10-year prostate cancer-specific survival approxi-
mating 95% [1].
Exclusion criteria are: previous pelvic irradiation, pre-
vious prostatectomy, World Health Organization
(WHO) performance score > 2 [22] (= symptomatic,
>50% during the day in bed, but not bedbound (score 3)
or bedbound (score 4)), International Prostate Symptom
Score (IPSS) ≥ 20, transurethral resection of the prostate
(TURP) within 3 months from start of the treatment,
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maker, metal implants or history of severe allergic reac-
tion after administration of contrast agent) or the use of
anti-coagulants that cannot be discontinued for the gold
markers implantation.
The study protocol is approved by the Medical Ethical
Committees of the participating hospitals. Written
informed consent will be obtained from all patients.
Randomization
Randomization is performed by an independent trial
center. If a patient meets the inclusion criteria and has
provided informed consent, the physician contacts the
trial center. To prevent randomly occurring differences
in important prognostic factors across the two rando-
mized groups, the randomization is stratified by TURP,
hormonal treatment and by centre. A TURP prior to
radiotherapy is associated with significantly more late
genitourinary toxicity [23,24]. The likely mechanism of
increased late toxicity is related to the relative devascu-
larisation of the urethra after TURP and the decreased
capability of the mucosa to repair sublethal damage
after radiotherapy [24]. Hormonal treatment is a prog-
nostic unfavorable factor for late genitourinary side
effects [23,25] and erectile impotence [26-28]. Further-
more, a protective effect for hormonal treatment is
reported for acute gastrointestinal side effects [23,29,30].
To prevent small numbers of patients in a particular
hospital from all receiving, by chance, the same treat-
ment, the hospital is chosen as one of the factors for
stratified randomization as well.
Time schedule
Between October 2009 and October 2010, the first 50
patients were included at the Department of Radiation
Oncology of the University Medical Center Utrecht.
Based on this accrual and the fact that other participat-
ing centers recently started to include patients as well,
we expect that the accrual will be completed within 5
years from start.
Radiotherapy
To minimize the positioning errors during treatment all
patients are treated with an online position verification
protocol using implanted fiducial gold markers
[14,31,32]. Radiotherapy will be delivered with advanced
radiotherapy techniques to be able to create adequate
dose distributions.
Am e a nd o s eo f7 7G yi n3 5f r a c t i o no f2 . 2G yi sp r e -
scribed to the entire prostate gland [33,34]. The dose in
the part of the PTV overlapping the rectum and bladder
is limited to keep the risk of severe gastrointestinal and
genitourinary toxicity acceptable.
To provide an accurate delineation of the prostate
gland with respect to the surrounding tissues [35,36],
the prostate is delineated on a computed tomography
(CT) scan combined with a registered magnetic reso-
nance imaging (MRI) scan. The rectum is contoured
from the anus or ischial tuberosities to the rectosigmoid
flexure or sacroiliac joints. The bladder is completely
outlined from the bladder neck to the dome.
The precise execution of the radiotherapy treatment
can differ in each participation center, but the treatment
will always meet the above mentioned criteria.
Intervention
Patients randomized to the experimental arm are treated
with the current standard of 77 Gy to the whole pros-
tate and in addition receive an integrated microboost to
the macroscopic tumor to reach a total dose of 95 Gy in
35 fractions of 2.7 Gy. To delineate the macroscopic
tumor within the prostate, different MR imaging techni-
ques are used. In addition to an anatomic T2 weighted
sequence, a combination of the following functional
imaging modalities can be used [37,38]. Dynamic con-
trast-enhanced (DCE)-MRI gives a characterization of
the tissue vasculature [39]. With this technique it is pos-
sible to detect areas with macroscopic tumor, because
tumors tend to contain higher density of leaky blood
vessels. With diffusion-weighted imaging (DWI)-MRI
the mobility of water molecules is measured [40].
Tumor tissue can be identified on DWI-MRI, because in
tumor the extracellular volume is reduced, leading to
reduced water diffusion in tumor tissue. MR spectro-
scopic imaging (MRS) provides metabolic information
with cancer regions showing higher choline and lower
citrate levels [41].
Primary endpoint
To evaluate whether the addition of an ablative micro-
boost to the macroscopic tumor within the prostate
increases the five-year freedom from biochemical failure
rate compared to the current standard of care. Biochem-
ical failure is defined according to the Phoenix definition
as a PSA rise of 2 ng/mL above the nadir PSA level [42].
The PSA level will be measured every six months until
10 years after treatment.
Secondary endpoints
Secondary endpoints are treatment-related toxicity, QoL
and disease-specific survival. Treatment-related toxicity
is measured by the Common Toxicity Criteria for
adverse events version 3.0 (CTCAE) [43]. The following
adverse events are scored: urinary frequency/urgency,
urinary retention, bladder spasms, urinary incontinence,
genitourinary hemorrhage, dysuria, rectal or perirectal
pain, proctitis, diarrhea, flatulence hemorrhoids, anal
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attendance scores the complaints before treatment,
acute toxicity (weekly during treatment and 4 weeks
after treatment) and late toxicity (every six months until
10 years after treatment). All symptoms are registered
even if they occur only on one single occasion. Grade >
2 is considered severe toxicity.General health-related
QoL is measured using the RAND-36 generic health
survey [44], cancer-specific QoL using the European
Organization for Research and Treatment of Cancer
(EORTC) core questionnaire (QLQ-C30) [45], and the
prostate tumor-specific QoL using the EORTC prostate
cancer module (QLQ-PR25) [46]. The disease- and
treatment-related side effects are only a component of
health-related quality of life [47]. To address the compo-
nents of overall well-being, a general instrument is used
in addition to the disease-specific questionnaires
[48-50]. The RAND-36 assesses physical and social
functioning, physical and emotional role restriction,
mental health, vitality, pain, general health and change
in health. The EORTC QLQ-C30 contains five func-
tional scales, three symptoms scales, a global QoL scale
and six single-items. The EORTC QLQ-PR25 assesses
urinary, bowel and sexual symptoms and functioning,
and the side effects of hormonal treatment. The first
questionnaire is handed over to the patient one week
before treatment at the Department of Radiation Oncol-
ogy and the next questionnaires are sent to the patient
every six months until 10 years after the completion of
the treatment. It is important to measure QoL every 6
months after treatment, to be able to determine the
point in time at which the QoL changes, for example
due to side-effects after treatment.
For disease-specific survival, death with metastases is
considered a death caused by the disease.
Safety
An independent data safety monitoring board (DSMB)
will evaluate the toxicity and clinical outcome. The
DSMB receives an update of the toxicity in total and
per treatment arm every 3 months. Serious toxicity,
defined as any acute or late toxicity requiring surgical
intervention, any grade 4 toxicity, and any not-transient
(duration >6 months) late toxicities grade 3, will imme-
diately be reported to the DSMB. An overview of the
percentage of biochemical recurrences per treatment
arm together with the evaluated number of patients per
arm will be sent to the DSMB yearly as well as a statisti-
cal comparison of the incidence of serious and less ser-
ious toxicities in the two arms. The DSMB decides on
stopping or continuing the trial. Exact rules cannot be
specified in advance, but an increase in the incidence of
toxicity (grade 3-4) with 5% or a smaller, but statistically
significant increase, are among the reasons to consider
stopping the trial. The DSMB can decide to prematurely
stop the trial in case the improvement in the experi-
mental arm is higher than anticipated in the trial design.
Sample size considerations
The statistical power of the study was calculated for the
primary endpoint (five-year freedom from biochemical
failure). Based on data of two randomized clinical trials
[2,51] reporting the treatment results of patients treated
with a radiation dose equal to the dose of the standard
arm of our trial, we expect that the five-year freedom
from biochemical failure of the standard arm will be
approximately 64%. We expect that an additional abla-
tive microboost to the macroscopic tumor will increase
this number with at least 10%. A one-sided log rank sur-
vival power analysis shows that the length of follow-up
after accrual of the last patient should be 3.5 years to
detect a difference of 10% (64% and 74% free from bio-
chemical failure after 5 years, in the control arm and
experimental arm, respectively) with a power of 80% at
a one-sided 5% significance level. This is under the
assumption that the patients enter the study during an
accrual period of 5 years, 50% of the enrollment is com-
plete when 70% of the accrual time has past and that
20% of the patients in both arms are lost to follow-up
during the follow-up period of 5 years. The reason to
choose a one sided p-value is that, although extremely
improbable, an increase in biochemical failure in the
experimental arm would lead to the same action as no
difference at all between the two treatment arms. This
is because the experimental treatment will only be
implemented if it is significantly better than the usual
treatment, due to the increased toxicity risk in the
experimental arm.
Data analysis
All analysis will be performed according to the inten-
tion-to-treat principle. Cox proportional hazards regres-
sion will be used to analyze differences in biochemical
failure and disease-specific survival between the two
treatment arms. Survival curves will be estimated by the
Kaplan-Meier technique. Differences between both
groups in the incidence of acute side-effects will be
tested with the Chi square test. The incidence of late
toxicity will be analyzed actuarially with the Kaplan-
Meier method, the log rank test and Cox regression
analysis. To analyze differences in QoL between the two
treatment groups over the time points, a general linear
model repeated-measures analysis of covariance will be
performed [52]. A change of 10% (or in general, 0.5
standard deviation) of the scale width is perceptible to
patients as a meaningful change [53]. Because of the
multiple comparisons for the QoL items, the p-value is
set at a conservative 0.01 for determining statistical
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include the QoL measures, a p-value of < 0.05 is consid-
ered statistically significant.
Inclusion of the first 50 patients
The first 50 patients included in the FLAME- trial, were
treated between October 2009 and October 2010 at the
Department of Radiation Oncology of the UMC Utrecht.
All patients received seven-beam intensity-modulated
radiotherapy (IMRT). A mean dose of 77 Gy in 35 frac-
tion of 2.2 Gy was prescribed to the planning target
volume (PTV) and at least 70 Gy was prescribed to 99%
of the PTV [33,34]. The radiation margin around the
prostate depends on several uncertainties in the daily
clinical practice [55-57]. For our institute based on
minimal positioning errors [32] and a simulation of
their impact on dose coverage [14], a PTV margin of 4
mm was chosen. We aimed at limiting the dose to the
rectum and bladder so that ≤ 5% of the rectum and ≤
10% of the bladder receives a dose of ≥ 72 Gy. Further-
m o r e ,av o l u m eo f1c co ft h eb l a d d e ra n dr e c t u m
receives a maximum dose of 80 Gy and 77 Gy, respec-
tively, and ≤ 50% of the rectum receives a dose of ≥ 50
Gy [34]. All treatment plans were checked by two inves-
tigators (UAH and MV) before start of the treatment.
The beam directions were 0º, 50º, 100º, 155º, 205º, 260º
and 310º. The location of the fiducial markers was
determined by visualizing the markers using portal
images of the first segment of the 0º beam and the 260º
beam. A difference of more than 1 mm compared to the
planning-CT was corrected online. After 5 fractions the
average rotation of the prostate was calculated. A rota-
tion of 3º around the anterior-posterior or the left-right
axis and a rotation of 6º around the cranio-caudal axis
was corrected by changing the gantry or table rotation
or the collimator angle. The portal images of the first
segment of the remaining beams were used to deter-
mine the average intrafraction prostate motion [58]. For
each patient the individual intrafraction and remaining
rotational errors were used to calculate the actual deliv-
ered doses to the target and the organs at risk.
The patients were treated in supine position. One
hour before the pretreatment planning scans and the
radiotherapy sessions, patients were instructed to drink
500 ml to create a full bladder. A full bladder during
radiotherapy results in a decreased amount of bladder
volume in the high dose region and a lower dose to
bowel loops compared to treatment with an empty blad-
der [59]. No antiflatulent diet or laxative was prescribed
[60]. When the rectum filling on CT and MRI differed
considerably, a new CT or MRI scan was performed, to
minimize the registration uncertainty between these two
imaging modalities.
For delineation of the macroscopic tumor within the
prostate, defined as the gross tumor volume (GTV),
anatomical and functional imaging was performed on a
3 Tesla MRI scanner (Achieva Philips Medical Systems,
Best, the Netherlands). The exam included 3 anatomical
scans: a multislice T2 weighted turbo spin echo (TSE)
sequence (TR/TE 8400/120 ms), a T1 weighted
sequence and a balanced turbo field echo (TFE)
sequence (TR/TE 2.8/1.4 ms, FOV = 25 cm, slice thick-
ness = 1 mm). The DCE-MRI protocol consists of a 3D
spoiled gradient echo sequence (TR/TE 4.0/1.0 ms, flip
angle 6º). Scans were repeated 120 times at 2.4 s inter-
val. A single acquisition consisted of 20 axial slices of
2.5 mm. The field of view was 40 × 40 cm
2,t h er e c o n -
struction matrix 160 × 160. For contrast enhancement,
0.1 mg/kg body weight gadobutrol (1.0 M (Gadovist,
Schering) was injected intraveneously. Trace-kinetics
modeling was done using the Tofts model [61] resulting
in 3D maps of the transfer constant K
trans.D i f f u s i o n -
weighted imaging scans were performed using a multi-
slice single shot SE-EPI sequence (FOV = 38 cm, slice
thickness = 3 mm, intersection gap = 1 mm, TR/TE =
5000/54 ms, acquisition matrix = 152 × 107, b values =
0, 300, 5000, 100 s/mm
2). The delineation of the GTV
was done by the treating physician and checked by two
investigators (UAH and MV) before start of the treat-
ment. To account for possible extracapsular extension,
the delineation of the macroscopic tumor was expanded
with an extra margin of 4 mm [62]. Figure 1 shows an
example of the delineation of the GTV and the dose dis-
tribution for a patient in the experimental arm. Table 1
shows the patient characteristics of the first 50 patients.
Twenty-three patients were randomized into the experi-
mental arm and 27 into the standard arm.
Discussion
The FLAME-trial is designed to investigate the effect of
an ablative microboost to the macroscopic tumor for
patients treated with external beam radiotherapy for
prostate cancer.
Previous studies demonstrated that the rate of toxicity
after high dose external beam radiotherapy with the use
of accurate position verification is low and consequently
high QoL is reported [34,63-66]. Planning studies showed
that an ablative microboost to the macroscopic tumor
was theoretically feasible within the currently used dose
constraints for rectum and bladder [15,67,68]. Further-
more, a feasibility study of Singh et al.[ 2 0 ]r e p o r t e d
excellent early toxicity after simultaneous integrated
IMRT boost of 95 Gy to the intraprostatic lesions. As a
result, with the use of optimal position verification com-
bined with the currently used dose constraints, the toxi-
city in the experimental treatment arm with the ablative
microboost of 95 Gy is expected to be acceptable.
Previous trials demonstrated a biochemical benefit of
dose escalation. However, up to now none of the dose
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disease specific or overall survival. However, all trials
were designed for biochemical survival instead of overall
or disease-specific survival due to the natural behavior
of prostate cancer. For this reason the FLAME-trial is
also powered for biochemical disease free survival. An
improvement in local control without a proven benefit
in overall survival is only acceptable when severe toxi-
city remains limited. Furthermore, to establish whether
a benefit in biochemical failure free survival also coun-
terbalances the negative aspects of dose escalation, such
as a small increase in toxicity, it is important that QoL
is taken into account. Therefore, repeated QoL measure-
ments are performed in patients included in this trial.
The precise delineation of the macroscopic tumor
within the prostate is a topic of ongoing research
[37,38,69]. In the FLAME-trial the delineation of the
macroscopic tumor is based on anatomical and func-
tional imaging according to the current opinion. The
different imaging techniques might show conflicting
results about the boundaries of the macroscopic tumor
area, leading to difficult delineation decisions. Therefore,
it is of major importance to investigate the precise loca-
tion of a recurrence and to establish what dose was pre-
scribed to that location. When a patient shows a rising
PSA without distant metastases, DCE-MRI and MRS
can be used to detect the location of recurrent prostate
cancer [70-74]. By correlating t h ed o s ed i s t r i b u t i o no f
the initial radiotherapy with the location of a local
recurrence, accurate dose-effect information can be
obtained. The dose-effect data generated from this ana-
lysis will help us to evaluate the required dose for each
cancer subunit and to provide a better understanding of
the different imaging techniques [38]. The dose distribu-
tions of the patients treated in the experimental arm,
are inhomogeneous with very low and very high deliv-
ered doses, and for that reason provide important dose-
effect information to create a reliable dose-effect curve.
A randomized study design is indicated to resolve the
problem of confounding effects. To our knowledge, no
other randomized controlled trials are being performed
to investigate the benefit of an ablative microboost to
the macroscopic tumor in prostate cancer patients.
Beside Singh et al. [20], three other groups performed a
Figure 1 Example of the delineation of the macroscopic tumor area (GTV) on T2 weighted MRI (a), an apparent diffusion coefficient
map derived from diffusion-weighted MRI (b) and a Ktrans parameter map obtained from dynamic contrast-enhanced MRI (c) and the
dose distribution (d).
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tumor region was delivered. Miralbell, et al. [16] treated
50 patients, after 64-64.4 Gy in 1.8-2 Gy fractions to the
whole prostate, with a hypofractionated boost of 2 frac-
tions of 5 to 8 Gy to the dominant tumor region, deli-
neated by anatomical imaging. After a median follow up
time of 63 months, a 5-year biochemical disease-free
and disease-specific survival of 98% and 100%, respec-
tively, were reported with acceptable long-term toxicity.
Gaudet et al. [17] selectively delivered a brachytherapy
hyperdosage of ≥ 216 Gy (150% of the prescribed dose)
to the macroscopic tumor, defined according to positive
areas on sextant biopsy, in 70 patients with localized
prostate cancer treated with permanent seed prostate
implant. No difference in acute or late toxicities com-
pared to 120 patients with a standard plan were seen.
Fonteyne et al. and De Meerleer et al. [18,19] performed
the largest trial in which 230 patients were treated with
am e a nd o s eo f8 1 - 8 2G yt oad o m i n a n tl e s i o n ,d e f i n e d
by T2 weighted MRI or MRI plus spectroscopy. With
the use of IMRT and daily ultra-sound based prostate
positioning, the acute toxicity remained low with no
grade 3 or 4 acute gastrointestinal toxicity and 7% grade
3 genitourinary toxicity.
Analyses of the actual delivered dose in the first 50
patients included in the FLAME-trial, revealed that it is
possible to deliver a high dose to the macroscopic
tumor area without compromising the dose constraints
for the nearby organs at risk. The influence of the
remaining intrafraction and rotational errors using an
online position verification protocol is minimal.
In conclusion, the aim of the FLAME-trial is to assess,
in patients treated with external beam radiotherapy for
prostate cancer, the potential benefit of an additional
ablative microboost to the macroscopic tumor on bio-
chemical control. In addition, the subgroup of patients
that will develop a local recurrence within the prostate
after treatment can be used to obtain accurate dose-
effect information for both the dominant lesion and
subclinical disease in prostate cancer.
The study protocol was approved by the Medical Ethi-
cal Committee. The trial is registered at http://Clinical-
Trials.gov (Registration identification number:
NCT01168479; URL: http://clinicaltrials.gov/ct2/show/
NCT01168479)
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prostate-specific antigen.
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